Opinion|Videos|November 11, 2023
Expert Insight and Future Perspectives for Follicular Lymphoma
Panelists close the discussion by offering insights and future perspectives on the treatment landscape for follicular lymphoma.
Advertisement
Episodes in this series
Advertisement
Related to this article
Rocbrutinib plus R-CHOP yielded a 100% ORR and an 86.7% CR rate in 15 patients with untreated non-GCB DLBCL, warranting randomized evaluation.
Grade 3/4 neurotoxicity in patients prompted a partial clinical hold on the PALISADES-1 and PALISADES-2 trials of KITE-753 in large B-cell lymphoma.
In a phase 2 trial, orelabrutinib plus sintilimab yielded a 60.7% overall response rate in relapsed/refractory primary CNS lymphoma.
Advertisement
Advertisement
Trending on CancerNetwork
1
KITE-753 Trials in R/R DLBCL Placed on Partial Clinical Hold for ICANS
2
AI-Measured Tumor Volume on PSMA PET-CT Linked With Survival in Prostate Cancer
3
How Could Rocbrutinib Plus R-CHOP Reshape Frontline Non-GCB DLBCL Treatment?
4
Managing FLOT Toxicity With Dose Reductions in Gastroesophageal Cancer
5